Australian Enterococcal Sepsis Outcome Progamme, 2011

Authors

  • Geoffrey W Coombs Australian Collaborating Centre for Enterococcus and Staphylococcus Species (ACCESS) Typing and Research, School of Biomedical Sciences, Curtin University, Perth, Western Australia; Department of Microbiology and Infectious Diseases, PathWest Laboratory Medicine, WA, Royal Perth Hospital, Perth, Western Australia
  • Julie C Pearson Department of Microbiology and Infectious Diseases, PathWest Laboratory Medicine, WA, Royal Perth Hospital, Perth, Western Australia
  • Denise A Daley Australian Group on Antimicrobial Resistance, Royal Perth Hospital, Perth, Western Australia
  • Tam Le Australian Collaborating Centre for Enterococcus and Staphylococcus Species (ACCESS) Typing and Research, School of Biomedical Sciences, Curtin University, Perth, Western Australia
  • James O Robinson Australian Collaborating Centre for Enterococcus and Staphylococcus Species (ACCESS) Typing and Research, School of Biomedical Sciences, Curtin University, Perth, Western Australia;Department of Microbiology and Infectious Diseases, PathWest Laboratory Medicine, WA, Royal Perth Hospital, Perth, Western Australia
  • Thomas Gottlieb Department of Microbiology and Infectious Diseases, Concord Hospital, Concord, New South Wales
  • Benjamin P Howden Microbiology Department, Austin Health, Heidelberg, Victoria; Department of Microbiology and Immunology, University of Melbourne, Melbourne, Victoria
  • Paul DR Johnson Microbiology Department, Austin Health, Heidelberg, Victoria
  • Catherine M Bennett Population Health, Deakin University, Melbourne
  • Timothy P Stinear Department of Microbiology and Immunology, University of Melbourne, Melbourne, Victoria
  • John D Turnidge SA Pathology, Department of Microbiology and Infectious Diseases, Women’s and Children’s Hospital, North Adelaide, South Australia; Departments of Pathology, Paediatrics and Molecular and Biomedical Sciences, University of Adelaide, Adelaide, South Australia
  • Australian Group on Antimicrobial Resistance

DOI:

https://doi.org/10.33321/cdi.2014.38.39

Keywords:

antimicrobial resistance surveillance, Enterococcus faecium, Enterococcus faecalis, vancomycin resistant, bacteraemia

Abstract

From 1 January to 31 December 2011, 29 institutions around Australia participated in the Australian Enterococcal Sepsis Outcome Programme (AESOP). The aim of AESOP 2011 was to determine the proportion of enterococcal bacteraemia isolates in Australia that are antimicrobial resistant, with particular emphasis on susceptibility to ampicillin and the glycopeptides, and to characterise the molecular epidemiology of the Enterococcus faecalis and E. faecium isolates. Of the 1,079 unique episodes of bacteraemia investigated, 95.8% were caused by either E. faecalis (61.0%) or E. faecium (34.8%). Ampicillin resistance was detected in 90.4% of E. faecium but not detected in E. faecalis. Using Clinical and Laboratory Standards Institute breakpoints (CLSI), vancomycin non-susceptibility was reported in 0.6% and 31.4% of E. faecalis and E. faecium respectively and was predominately due to the acquisition of the vanB operon. Approximately 1 in 6 vanB E. faecium isolates however, had an minimum inhibitory concentration at or below the CLSI vancomycin susceptible breakpoint of ≤ 4 mg/L. Overall, 37% of E. faecium harboured vanA or vanB genes. Although molecular typing identified 126 E. faecalis pulsed-field gel electrophoresis (PFGE) pulsotypes, more than 50% belonged to 2 pulsotypes that were isolated across Australia. E. faecium consisted of 73 PFGE pulsotypes from which 43 multilocus sequence types were identified. Almost 90% of the E. faecium were identified as clonal complex 17 clones, of which approximately half were characterised as sequence type 203, which was isolated Australia-wide. In conclusion, the AESOP 2011 has shown that although polyclonal, enterococcal bacteraemias in Australia are frequently caused by ampicillin-resistant vanB E. faecium. Commun Dis Intell 2014;38(3):E247–E252.

Downloads

Download data is not yet available.

References

Pinholt M, Ostergaard C, Arpi M, Bruun NE, Schønheyder HC, Gradel KO, et al. Incidence, clinical characteristics and 30-day mortality of enterococcal bacteraemia in Denmark 2006–2009: a population-based cohort study. Clin Microbiol Infect 2014;20(2):145–515.

Deshpande LM, Fritsche TR, Moet GJ, Biedenbach DJ, Jones RN. Antimicrobial resistance and molecular epidemiology of vancomycin-resistant enterococci from North America and Europe: a report from the SENTRY antimicrobial surveillance program. Diagn Microbiol Infect Dis 2007;58(2):163–170.

Murray BE. The life and times of the Enterococcus. Clin Microbiol Rev 1990;3(1):46–65.

Simonsen GS, Småbrekke L, Monnet DL, Sórensen TL, Moller JK, Kristinsson KG, et al. Prevalence of resistance to ampicillin, gentamicin and vancomycin in Enterococcus faecalis and Enterococcus faecium isolates from clinical specimens and use of antimicrobials in five Nordic hospitals. J Antimicrob Chemother 2003;51(2):323–331.

Treitman AN, Yarnold PR, Warren J, Noskin GA. Emerging incidence of Enterococcus faecium among hospital isolates (1993 to 2002). J Clin Microbiol 2005;43(1):462–463.

Frieden TR, Munsiff SS, Low DE, Willey BM, Williams G, Faur Y, et al. Emergence of vancomycin-resistant enterococci in New York City. Lancet 1993;342 (8863):76–79.

Murray BE. Vancomycin-resistant enterococcal infections. N Engl J Med 2000;342(10):710–721.

European Centre for Disease Prevention and Control. European Antimicrobial Resistance Surveillance Network. [online]. Accessed on April 2014. Available from: http://www.ecdc.europa.eu/en/activities/surveillance/EARS-Net/Pages/index.aspx

Bearman GM, Wenzel RP. Bacteremias: A leading cause of death. Arch Med Res 2005 36(6):646–659.

Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009;48(1):1–12.

Christiansen KJ, Turnidge JD, Bell JM, George NM, Pearson JC, Australian Group on Antimicrobial Resistance. Prevalence of antimicrobial resistance in Enterococcus isolates in Australia, 2005: Report from the Australian Group on Antimicrobial Resistance. Commun Dis Intell 2007;31(4):392–397.

Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Twenty-second informational supplement M100-S22. Villanova, PA, USA; 2012.

Kulski JK, Wilson RD, Bending R, Grubb W. Antibiotic resistance and genomic analysis of enterococci in an intensive care unit and general wards. Pathology 1998;30(1):68–72.

Tenover FC, Arbeit RD, Goering RV, Mickelsen PA, Murray BE, Persing DH, et al. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: Criteria for bacterial strain typing. J Clin Microbiol 1995;33(9):2233–2239.

Homan WL, Tribe D, Poznanski S, Li M, Hogg G, Spalburg E, et al. Multilocus sequence typing scheme for Enterococcus faecium. J Clin Microbiol 2002;40(6):1963–1971.

Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: Analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004;39(3):309–317.

de Kraker ME, Jarlier V, Monen JC, Heuer OE, van de Sande N, Grundmann H. The changing epidemiology of bacteraemias in Europe: Trends from the European Antimicrobial Resistance Surveillance System. Clin Microbiol Infect 2013;19(9):860–868.

Klare I, Fleige C, Geringer U, Witte W, Werner G. Performance of three chromogenic VRE screening agars, two Etest® vancomycin protocols, and different microdilution methods in detecting vanB genotype Enterococcus faecium with varying vancomycin MICs. Diagn Microbiol Infect Dis 2012;74(2):171–176.

Mendes RE, Farrell DJ, Sader HS, Jones RN. Oritavancin microbiologic features and activity results from the surveillance program in the United States. Clin Infect Dis 2012;54(Suppl 3):S203–S213.

Jones RN, Sader HS, Flamm RK. Update of dalbavancin spectrum and potency in the USA: report from the SENTRY Antimicrobial Surveillance Program (2011). Diagn Microbiol Infect Dis 2013;75(3):304–307.

Soderblom T, Aspevall O, Erntell M, Hedin G, Heimer D, Hokeberg I, et al. Alarming spread of vancomycin resistant enterococci in Sweden since 2007. Euro Surveill 2010;15(29):pii: 19620.

López M, Cercenado E, Tenorio C, Ruiz-Larrea F, Torres C. Diversity of clones and genotypes among vancomycin-resistant clinical Enterococcus isolates recovered in a Spanish hospital. Microb Drug Resist 2012;18(5):484–491.

Werner G, Klare I, Fleige C, Geringer U, Witte W, Just HM, et al. Vancomycin-resistant vanB-type Enterococcus faecium isolates expressing varying levels of vancomycin resistance and being highly prevalent among neonatal patients in a single ICU. Antimicrob Res Infect Control 2012;1(1):21.

McCracken M, Wong A, Mitchell R, Gravel D, Conly J, Embil J, et al. Molecular epidemiology of vancomycin-resistant enterococcal bacteraemia: results from the Canadian Nosocomial Infection Surveillance Program, 1999–2009. J Antimicrob Chemother 2013;68(7):1505–1509.

Klare I, Witte W, Wendt C, Werner G. [Vancomycin-resistant enterococci (VRE). Recent results and trends in development of antibiotic resistance]. Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz 2012;55(11–12):1387–400. German.

Downloads

Published

01/09/14

How to Cite

Coombs, Geoffrey W, Julie C Pearson, Denise A Daley, Tam Le, James O Robinson, Thomas Gottlieb, Benjamin P Howden, et al. 2014. “Australian Enterococcal Sepsis Outcome Progamme, 2011”. Communicable Diseases Intelligence 38 (September):247-52. https://doi.org/10.33321/cdi.2014.38.39.

Issue

Vol. 38 (2014)

Section

Annual report

Categories

License

Copyright (c) 2014 Communicable Diseases Intelligence

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Most read articles by the same author(s)

1 2 3 4 5 6 > >>